Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003630:Daunorubicin / Q000008:administration & dosage*; D017277:Drug Approval; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D003630:Daunorubicin